非酒精性脂肪肝
医学
代谢综合征
脂肪肝
血脂异常
2型糖尿病
疾病
糖尿病
内科学
背景(考古学)
肥胖
胰岛素抵抗
脂肪性肝炎
生物信息学
内分泌学
作者
Emir Muzurović,Carol Chiung-Hui Peng,Matthew J Belanger,Despina Sanoudou,Dimitri P Mikhailidis,Christos S. Mantzoros
出处
期刊:Hypertension
[Ovid Technologies (Wolters Kluwer)]
日期:2022-04-25
卷期号:: 101161HYPERTENSIONAHA12217982-101161HYPERTENSIONAHA12217982
标识
DOI:10.1161/hypertensionaha.122.17982
摘要
The prevalence of nonalcoholic fatty liver disease (NAFLD) is rising. NAFLD/nonalcoholic steatohepatitis (NASH) is associated not only with hepatic morbidity and mortality but also with an increased cardiovascular risk. NAFLD and cardiovascular disease (CVD) share several risk factors, such as obesity, metabolic syndrome, hypertension, dyslipidemia, type 2 diabetes, and chronic kidney disease. This review summarizes the evidence linking cardiometabolic risk factors and NAFLD in the context of risk for CVD. The cause of NAFLD/NASH is complex, involving a range of factors from genetics to lifestyle and energy balance. Genetically driven high liver fat content does not appear to be causally associated with increased CVD risk. In contrast, metabolic dysfunction not only predisposes to liver pathology but also leads to a significantly higher CVD risk. Given that NAFLD pathophysiology is influenced by multiple factors, each patient is unique as to their risk of developing CVD and liver pathology. At the same time, the rising burden of NAFLD/NASH is closely linked with the global increase in metabolic disorders, including obesity and type 2 diabetes. Therefore, both personalized therapeutic approaches that recognize individual pathophysiology, as well as public health policies that address the root causes of cardiometabolic risk factors for NAFLD may be needed to effectively address the NAFLD/NASH epidemic.
科研通智能强力驱动
Strongly Powered by AbleSci AI